Pipeline
We develop disease-directed Lock-antibody for safer therapy
Besides providing platform service, PrecisemAb also utilizes antibody lock technology to develop potential Lock-antibody products in the area of autoimmune disease, surface marker, immunotherapy and antibody drug conjugate.
Pipeline
Industrial Applications
Surface Marker
EGFR、CD3 X CD20
Antibody Drug Conjugate (ADC)
Lock-ADC
Immunotherapy
PD-1、CLTA4、4-1BB、CD28、CD47
Autoimmune Disease
TNF-α、IL-1β
請填入內容
Cancer
Cancer cells often overexpress specific proteins to support their survival and proliferation. One common target is the epidermal growth factor receptor (EGFR), which is highly expressed in cancers such as head and neck and colorectal cancer. However, EGFR is also widely present in normal epithelial cells, making traditional anti-EGFR therapies prone to skin-related side effects. To address this, PrecisemAb developed PSM101 using its Universal Antibody Lock Technology, which ensures antibody activation occurs only within the tumor microenvironment. This allows precise targeting of cancer cells while minimizing harm to healthy tissue. PSM101 is now in large-scale production.
Antibody-Drug Conjugates (ADCs)
ADCs are a growing class of cancer therapies that use antibodies to deliver cytotoxic drugs directly to tumors. By combining the targeting capability of antibodies with the potency of chemotherapy, ADCs aim to enhance tumor suppression. However, there are risks—premature drug release outside tumor sites or non-specific uptake by healthy tissues can lead to serious side effects.
Immunotherapy
Checkpoint inhibitors work by activating immune cells or blocking their inhibition to kill tumors. However, these antibodies may unintentionally activate immune responses in non-target tissues, leading to cytokine storms or inflammation in organs, causing discomfort or severe side effects. Animal studies have demonstrated that PrecisemAb’s Universal Antibody Lock Technology reduces these risks while maintaining strong anti-tumor activity.
Autoimmune Diseases
TNF-α is an immune signaling protein that helps the body defend against pathogens by triggering cell death and inflammation. Excess TNF-α, however, can cause chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease. While current anti-TNF-α antibodies can neutralize the cytokine and reduce symptoms, they may also impair immune defense in healthy tissues, increasing the risk of infections. PrecisemAb’s antibody has demonstrated stronger therapeutic effects and a significantly improved safety profile in preclinical studies.
TOP